Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466627 | 1.00 | DYRK1A (0.49) | DYRK1ATRPV1NQO2KDM4APDPK1 | |
| SCHEMBL21819943 | 0.90 | MAOB (0.47) | DYRK1ANQO2 | |
| SCHEMBL5123403 | 0.87 | AKR1B1 (0.49) | DYRK1ATRPV1KDM4APDPK1AKR1B1 | |
| SCHEMBL20509355 | 0.87 | DYRK1A (0.48) | DYRK1ATRPV1KDM4APDPK1RAB9A | |
| SCHEMBL30466621 | 0.87 | DYRK1A (0.48) | DYRK1ATRPV1KDM4APDPK1RAB9A | |
| SCHEMBL24962449 | 0.87 | HDAC6 (0.52) | DYRK1ATRPV1MAPTAKR1B1 | |
| SCHEMBL24962455 | 0.85 | AKR1B1 (0.55) | DYRK1ATRPV1AKR1B1 | |
| SCHEMBL24962469 | 0.85 | DYRK1A (0.47) | DYRK1ATRPV1KDM4APDPK1GLS | |
| SCHEMBL24963248 | 0.84 | PPARA (0.49) | DYRK1ATRPV1KDM4APDPK1GLS | |
| SCHEMBL30493007 | 0.84 | DYRK1A (0.48) | DYRK1ATRPV1KDM4APDPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-3601224-B1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2023-07-05 | — | — | EP | disclosed |
| CN-110914238-B | Compounds as antibiotics | 安塔比奥公司 | 2023-06-20 | — | — | CN | disclosed |
| US-11000511-B2 | Chemical compounds as antibiotics | ANTABIO SAS (FR) | 2021-05-11 | — | — | US | disclosed |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2020-05-21 | — | — | US | disclosed |
| CN-110914238-A | Compounds as antibiotics | 安塔比奥公司 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | MRPL21, CFTR, H1-0 | DYRK1A 2270/4885TRPV1 2535/4885NQO2 31/4885 |
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | DYRK1A 2557/4885TRPV1 552/4885NQO2 411/4885 |
| US-11000511-B2 | Chemical compounds as antibiotics | MRPL21, CFTR, H1-0 | DYRK1A 2270/4885TRPV1 2535/4885NQO2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.